Abstract A relationship between hyperammonemia and Ureaplasma infection has been shown in lung transplant recipients. We have demonstrated that Ureaplasma urealyticum causes hyperammonemia in a novel immunocompromised murine model. Herein, we determined whether Ureaplasma parvum can do the same. Male C3H mice were given mycophenolate mofetil, tacrolimus, and prednisone for 7 days, and then challenged with U. parvum intratracheally (IT) and/or intraperitoneally (IP), while continuing immunosuppression over 6 days. Plasma ammonia concentrations were determined and compared using Wilcoxon rank-sum tests. 
Introduction
Hyperammonemia has been reported in a number of types of transplant recipients, most commonly lung transplant recipients [1] [2] [3] [4] [5] [6] . In a recent retrospective cohort study involving 8 07 lu ng tr an s pl an t r ec i p i en t s , 1 % d e v el op e d hyperammonemia, 75 % of whom died [1] . Until recently, the cause of hyperammonemia in transplant recipients was unclear. Using specialized culture and an Ureaplasma parvum/urealyticum nucleic acid amplification test [7] , we recently described a relationship between Ureaplasma infection and hyperammonemia in lung transplant recipients [4] . Based on this finding, we administered an immunosuppression regimen mimicking that administered to lung transplant recipients to laboratory mice, and showed that they developed hyperammonemia when challenged with a type strain of U. urealyticum [8] . In this study, we showed that the related organism, U. parvum, can also cause hyperammonemia in pharmacologically immunosuppressed mice.
Materials and methods

Microorganism
A clinical U. parvum isolate (IDRL-10,774, multilocus sequence type 22 [9] ) recovered from the bronchial washings of a lung transplant patient was studied. The patient from whom the isolate had been recovered was a 65-year-old man with idiopathic pulmonary fibrosis who had undergone bilateral lung transplantation. Two days post-transplant, he had been noted to be lethargic; 5 days post-transplant he had developed acute mental status changes and hypoxia triggering intubation and mechanical ventilation. Seven days post-transplant, he had developed seizures; his ammonia level had been 1,100 μmol/L on the 8th post-transplant day. The following day, computed tomography of the head had shown cerebral edema and herniation, and he had died on the 10th posttransplant day. A bronchial washing from 3 days post-transplant, tested posthumously, was culture-positive for the U. parvum strain studied here.
Inoculum was prepared by growing the organism in U9 broth (Hardy Diagnostics, Santa Maria, CA, USA) at 37°C in room air until an orange color change was observed (∼5 h). The culture broth was then centrifuged at 4,000 rpm for 30 min to concentrate the cells. The final inoculum concentration ranged from 5 × 10 10 to 2 × 10 11 CFU/mL. For morphological identification and quantitation, U. parvum was plated onto A8 agar (Hardy Diagnostics) and incubated anaerobically at 37°C for 5 days. Colonies were enumerated by using ×100 microscopy. Freshly-prepared inoculum was used to challenge the mice.
Immunosuppressive agents
Mice were pharmacologically immunosuppressed using intraperitoneal (IP) mycophenolate mofetil (90 mg/kg; Cellcept Intravenous, Roche Laboratories, Nutley, NJ, USA), IP tacrolimus (1.2 mg/kg; Prograf, Astellas Pharma, Northbrook, IL, USA), and oral prednisone (6 mg/kg; Prednisone Intensol, Roxane Laboratories, Columbus, OH, USA) administered daily for 7 days before the challenge with U. parvum and continued over 6 days of microbial challenge (i.e., until the day before sacrifice).
Experimental mouse model
Immunocompetent C3H male mice (24-29 g, Charles River Laboratories, Wilmington, MA, USA) were studied. As controls, normal mice were studied (n = 12), with additional controls consisting of mice receiving the immunosuppression regimen for 13 days (n = 12), and immunocompetent mice (n = 12) challenged with U. parvum IT/IP. Pharmacologically immunosuppressed mice were challenged with U. parvum in U9 broth over 6 days by IP challenge every day (n = 21), or by IP challenge every day combined with IT challenge every other day (n = 27). For IT challenge, mice were anesthetized with ketamine/xylazine (90/10 mg/kg) and placed in a vertical position; 50 μL of U. parvum suspension was placed into the trachea using a 22G curved gavage needle. Mice remained vertical for 2 min and were monitored until awake. For IP challenge, 500 μL of U. parvum suspension was injected into the peritoneum. A fourth group of control animals (n = 18) consisted of immunosuppressed mice challenged IT/IP with spent U9 broth (filtered through a 0.1-μm filter). U. parvum challenge was administered 5 h after the administration of immunosuppressive agents. Animals were monitored for decreased activity, decreased body temperature (as assessed by touch), hunched stature, distress, and inability to eat and drink; if these findings were severe, animals were euthanized. Eleven mice died before the experimental endpoint. Because of the rapid coagulation of blood, the blood of most deceased mice was unobtainable for determination of ammonia.
Measurement of plasma ammonia concentrations
Mice were euthanized with CO 2 asphyxiation 24 h after the last IP and 48 h after the last IT challenge. Blood was collected via cardiac puncture and placed into 1.5-mL EDTA tubes. EDTA blood was immediately centrifuged at 8,000 rpm for 3 min and plasma frozen at −80°C. Plasma ammonia concentrations were determined using a Vitros 350 (Ortho Clinical Diagnostics, Raritan, NJ, USA).
U. parvum culture
Cardiac blood, lung tissue and a peritoneal cavity swab were cultured for U. parvum in U9 broth at 37°C for 5 days. Owing to color changes in the U9 media, a maximum of 50 μL of blood could be cultured. Whole lungs were homogenized with 3 mL of MicroTest M5 transport media (Remel; Lenexa, KS, USA); 200 μL of tissue homogenate was cultured. Positive cultures were confirmed by plating to A8 agar and by a previously described real-time PCR assay [7] , performed here using a LightCycler 1.5 real-time PCR instrument (Roche Diagnostic, Mannheim, Germany) and with probe dye Red-640.
Statistical analysis
Plasma ammonia concentrations of the study groups were compared using Wilcoxon rank-sum tests. All tests were two-sided; p values less than 0.05 were considered statistically significant. No adjustment for multiple comparisons was made because of the small sample sizes. Analysis was performed using SAS version 9.4 (SAS, Cary, NC, USA).
Results
Plasma ammonia concentrations
The plasma ammonia concentrations of normal (nonimmunosuppressed, uninfected) C3H mice were 154-284 μmol/L (median, 226 μmol/L), whereas those of uninfected immunosuppressed mice were 122-340 μmol/L (median, 231 μmol/L) and those of immunocompetent mice challenged IT/IP with U. parvum were 130-330 μmol/L (median, 226 μmol/L). The plasma ammonia concentrations of pharmacologically immunosuppressed mice challenged with spent U9 vehicle IT/IP were 102-340 μmol/L (median, 188 μmol/ L). There was no difference in the plasma ammonia concentrations in this fourth group compared with the first three control groups (p values are shown in Table 1 ).
Mice in the IT/IP challenge group had elevated plasma ammonia concentrations (median 343 μmol/L, range 136-1,000 μmol/L) compared with vehicle IT/IP negative control mice (p < 0.001). Mice in the IP challenge group also had elevated plasma ammonia concentrations (median 307 μmol/ L, range 132-692 μmol/L) compared with vehicle IT/IP negative control mice (p < 0.001). A comparison of plasma ammonia concentrations for each group is shown in Fig. 1 .
U. parvum culture
Culture results are shown in the Table 1 . Uninfected immunosuppressed mice, IT/IP-challenged immunocompetent mice, and spent U9 IT/IP vehicle control mice had negative cultures. Among the immunosuppressed mice challenged with U. parvum IP or IT/IP, all cardiac blood culture results were negative. In immunosuppressed mice challenged with IT/IP U. parvum, 68 % of lung tissues were culture-positive (13 out of 19), and 47 % of mice (9 out of 19) were both lung and peritoneal swab culture-positive. All mice in the IP challenge group had culture-negative lung tissues, but 40 % (8 out of 20) had positive peritoneal swab cultures. Among immunocompetent mice challenged with U. parvum IT/IP, 50 % of lung tissues (6 out of 12) and 42 % of peritoneal swabs (5 out of 12) were culture-positive. Only 25 % of these immunocompetent mice challenged IT/IP were both lung and peritoneal swab culture-positive (3 out of 12).
Immunosuppressed mice challenged with U. parvum IT/IP were divided into lung culture-positive and -negative subgroups (Fig. 2) ; there was no difference in ammonia concentrations between the two subgroups (p = 0.43). Similarly, immunosuppressed mice challenged with U. parvum IP were divided into peritoneal swab culture-positive and -negative subgroups (Fig. 2) ; ammonia levels were similar in the subgroups (p = 0.94).
Mortality before the experimental endpoint
Eleven animals died before the planned experimental endpoint and are therefore not included in Table 1 (except in the footnote) or in Figs. 1 or 2 ; details are shown in the footnote to the Table 1 . IT intratracheal, IP intraperitoneal, NA not applicable *p value for ammonia concentrations compared with spent vehicle broth a Two deaths before the experimental endpoint (days 10 and 12), attributed to anesthesia and IT challenge b Eight deaths before the experimental endpoint. One mouse died on day 11 after having been noted to feel cool to the touch. One mouse developed bladder enlargement and died after immunosuppressive drug administration on day 11; it was not possible to assess its ammonia level, but blood and bladder aspirate cultures were positive. One mouse was sacrificed on day 11 because of tachypnea, hunched stature and lethargy; cultures of blood, lung, and a peritoneal swab were positive and ammonia was 955 μmol/L. Four mice died after IT/IP inoculation on day 12, of which 2 developed an enlarged bladder and died about 15 min after IT/IP inoculation with ammonia levels >1,000 μmol/L and positive blood and bladder aspirate cultures. One mouse was sacrificed on day 12 because of tachypnea, hunched stature, and lethargy; cultures of lung and a peritoneal swab were positive and ammonia was 326 μmol/L. c One death just before sacrifice on day 14; the animal had hunched stature and lethargy after inoculation on day 13
Discussion
Recently, we established an immunocompromised experimental mouse model in which we showed that U. urealyticum ATCC 27618 can cause hyperammonemia [8] . Here, we show that a clinical U. parvum isolate can cause hyperammonemia using the same model. U. urealyticum and U. parvum produce large amounts of urease, which hydrolyzes urea to produce ATP, generating ammonia in the process [10] . These organisms may cause urogenital infections in immunocompetent adults and invasive diseases, such as pneumonia and bacteremia, in neonates [11] . Since they cannot grow in or on routine laboratory culture media, clinicians and microbiologists may overlook them as causes of infection or, as reported herein, a metabolic syndrome. Hyperammonemia syndrome is a rare, acute and fatal complication of lung transplantation, reported to occur in 1-4.1 % of lung transplant recipients; onset is typically within the first 2 weeks post-transplant [1, 12] . We have described a relationship between Ureaplasma infection and hyperammonemia in lung transplant recipients [4] . Consistent with findings in humans infected with Ureaplasma species, some of our experimental mice showed acute-onset hyperammonemia during a 13-day period of immunosuppression, with a few mice dying with hyperammonemia and positive blood cultures.
Similar to the results of our previous study with U. urealyticum [8] , none of the mice not receiving pharmacological immunosuppression challenged IT/IP with U. parvum developed elevated plasma ammonia concentrations, whereas immunosuppressed mice challenged with U. parvum IT/IP or IP had higher plasma ammonia levels (up to 1,000 μmol/L) than vehicle-challenged controls (p < 0.001). Additionally, in this study, we were able to measure plasma ammonia concentrations of a few mice that died just before the experimental endpoint and found ammonia concentrations up to 1,000 μmol/L or greater. Thus, the ability of two Ureaplasma species, U. urealyticum and U. parvum, to cause hyperammonemia has now been established in our immunocompromised murine model. Compared with our previous U. urealyticum-related hyperammonemia study using the same model, more lung cultures were positive in U. parvum IT/IP-challenged mice. Two factors may explain this finding. First, the amount of U. parvum inoculum used in this study was greater than the amount of U. urealyticum inoculum used in our previous study. Second, a clinical U. parvum strain, that had caused hyperammonemia in a lung transplant recipient, was used in this study. This clinical strain may be more virulent (e.g., have stronger adherence to respiratory epithelium) or possibly be a stronger urease producer than the type strain of U. urealyticum studied previously. Interestingly, culture positivity did not correlate with high ammonia concentrations. Immunocompetent mice challenged with U. parvum IT/IP had positive cultures with normal ammonia levels. Among immunosuppressed mice challenged with U. parvum IP or IT/IP, those with positive lung or peritoneal swab cultures did not have higher ammonia levels than mice with negative cultures. In our unpublished experiments using NOD SCID mice (severe combined immunodeficiency mice with nonobese diabetic background, weighing 23-29 g; Charles River Laboratories, Wilmington, MA, USA) challenged with U. urealyticum and U. parvum, we did not observe hyperammonemia (data not shown). The role of specific immunosuppressive agents in Ureaplasma-associated hyperammonemia and correlates of protection against both infection and hyperammonemia deserve to be investigated further. Our animal model enables further research on the pathogenesis, treatment, and prophylaxis of Ureaplasma-related hyperammonemia.
In conclusion, using a clinical strain isolated from the respiratory tract of a lung transplant recipient who died of hyperammonemia syndrome, we have verified that U. parvum can cause hyperammonemia in pharmacologically immunosuppressed mice.
